MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

MDT

89.34

+0.27%↑

VEEV

281.18

-0.98%↓

A

124.13

+2.21%↑

WBA

11.54

-0.09%↓

HQY

97.12

-2.5%↓

Search

Allogene Therapeutics Inc

Suletud

SektorTervishoid

1.25 4.17

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.2

Max

1.31

Põhinäitajad

By Trading Economics

Sissetulek

206K

-60M

Kasumimarginaal

272,450

Töötajad

226

EBITDA

-302K

-56M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+552.89% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. aug 2025

Turustatistika

By TradingEconomics

Turukapital

4.4M

260M

Eelmine avamishind

-2.92

Eelmine sulgemishind

1.25

Uudiste sentiment

By Acuity

50%

50%

168 / 376 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Allogene Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. juuli 2025, 21:42 UTC

Omandamised, ülevõtmised, äriostud

Justice Department Won't Seek Injunction for T-Mobile Acquisition of U.S. Cellular

10. juuli 2025, 17:06 UTC

Omandamised, ülevõtmised, äriostud

Portugal Begins Process to Sell Stake in National Carrier -- Update

10. juuli 2025, 17:00 UTC

Suurimad hinnamuutused turgudel

K Wave Media Shares Drop After Convertible Note Agreement With Anson Funds

10. juuli 2025, 16:31 UTC

Omandamised, ülevõtmised, äriostud

Blackstone Makes $664 Million Counteroffer for Warehouse REIT Amid Bidding War -- 2nd Update

10. juuli 2025, 23:47 UTC

Market Talk

Gold Edges Higher Amid Lingering Global Trade Tensions -- Market Talk

10. juuli 2025, 23:40 UTC

Market Talk

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

10. juuli 2025, 22:36 UTC

Market Talk

Tourism Holdings' Profit Warning Less Concerning Than Others -- Market Talk

10. juuli 2025, 22:23 UTC

Market Talk

New Law Creates Winners and Losers Among Renewable-Energy Projects -- Market Talk

10. juuli 2025, 20:50 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

10. juuli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10. juuli 2025, 20:00 UTC

Omandamised, ülevõtmised, äriostud

Toyota Tsusho America Completes Acquisition of Radius Recycling

10. juuli 2025, 19:56 UTC

Market Talk

Gold Rises on Inflation Concerns -- Market Talk

10. juuli 2025, 19:33 UTC

Market Talk

Oil Snaps Winning Streak As Oversupply Concerns Return -- Market Talk

10. juuli 2025, 19:21 UTC

Market Talk

U.S. Natural Gas Rebound on Benign Storage Build -- Market Talk

10. juuli 2025, 18:46 UTC

Market Talk

Mexican Industrial Production Seen as Mixed in May -- Market Talk

10. juuli 2025, 18:15 UTC

Market Talk

Brazil's Bullish Outlook Expected to Survive Trump Tariffs -- Market Talk

10. juuli 2025, 18:03 UTC

Market Talk
Tulu

Travel Agency Investors Cautiously Optimistic After Delta Report -- Market Talk

10. juuli 2025, 17:57 UTC

Market Talk

US Labor Shortage Could Weigh on Business, Economic Growth -- Market Talk

10. juuli 2025, 17:34 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Conagra Falls While Simply Good Foods Adapts. What's Eating Food Companies. -- Barrons.com

10. juuli 2025, 17:34 UTC

Market Talk

Canada Vows Fight Over Trump's Copper Tariffs -- Market Talk

10. juuli 2025, 17:20 UTC

Market Talk

Copper Climbs as Futures Wrangle With Trump Tariff -- Market Talk

10. juuli 2025, 17:20 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

10. juuli 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

10. juuli 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

10. juuli 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

10. juuli 2025, 16:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10. juuli 2025, 16:02 UTC

Market Talk

Global Equities Roundup: Market Talk

10. juuli 2025, 16:02 UTC

Market Talk

Embraer Expected to Bear Brunt of U.S. Tariffs on Brazil -- Market Talk

10. juuli 2025, 16:01 UTC

Omandamised, ülevõtmised, äriostud

Investor AB: Advanced Instruments' Acquisition of Nova Biomedical Completed

10. juuli 2025, 15:41 UTC

Market Talk

U.S. Natural Gas Storage Surplus Holds Steady -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Allogene Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

552.89% tõus

12 kuu keskmine prognoos

Keskmine 7.9 USD  552.89%

Kõrge 14 USD

Madal 1 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Allogene Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

11

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.18 / 1.69Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

168 / 376 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.